🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

76 results for “General” Clear

  1. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 small molecule active

    1 trial

  2. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  3. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 2 mab completed

    1 trial

  4. PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures

    phase 2 small molecule active

    1 trial

  5. Placebo

    Regeneron UK Limited

    Generalized Lipodystrophy

    phase 2 small molecule completed

    1 trial

  6. Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  7. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  8. SPD503 (extended-release Guanfacine hydrochloride)

    Takeda

    Generalized Anxiety Disorder (GAD)

    phase 2 small molecule completed

    1 trial

  9. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    phase 2 small molecule active

    1 trial

  10. Sugammadex Injection 2mg/kg

    BRIGHT MINDS BIOSCIENCES INC.

    Anesthesia, General

    phase 2 small molecule completed

    1 trial

  11. Tocilizumab Injectable Product

    Tang-Du Hospital

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  12. Uplizna 100 mg concentrate for solution for infusion

    Amgen

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  13. YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  14. anti-CD133-CAR vector-transduced T cells

    Chinese PLA General Hospital

    Liver Cancer

    phase 2 mab completed

    1 trial

  15. raltitrexed combined with apatinib

    Chinese PLA General Hospital

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  17. 0.33% ropivacaine 250ml

    Guangzhou General Hospital of Guangzhou Military Command

    Pain

    approved small molecule completed

    1 trial

  18. Sertraline

    United Therapeutics Europe Ltd

    Generalised Anxiety Disorder

    approved small molecule terminated

    1 trial

  19. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    approved small molecule active

    3 trials

  20. Sugammadex hameln 100 mg/ml oplossing voor injectie, Naloxon HCl Accord 0,4 mg/ml, oplossing voor injectie / infusie in een voorgevulde spuit, ANEXATE 0,5 mg/5 ml, solution injectable (I.V.), REMIMAZOLAM , Sufentanil Viatris 5 microgram/ml oplossing voor injectie, Esmeron 10 mg/ml, oplossing voor injectie

    Disc Medicine

    General anesthesia

    approved small molecule active

    1 trial

  21. Vyvgart 20 mg/mL concentrate for solution for infusion

    The George Institute

    Patients affected by generalized myasthenia gravis

    approved small molecule active

    1 trial

  22. General Anesthesia

    United Therapeutics Europe Ltd

    Facial Injuries

    small molecule completed

    1 trial

  23. Routine Medication

    The First People's Hospital of Lianyungang

    Generalized Anxiety Disorder

    small molecule active

    1 trial

  24. Sevoflurane

    The First People's Hospital of Lianyungang

    Anesthesia, General

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources